Multiple Myeloma Coverage from Every Angle
Editor:
Shaji K. Kumar, MD
Advertisement
Advertisement

Available Clinical Trials

A phase 2 study of elranatamab as consolidation after idecabtagene vicleucel in relapsed refractory multiple myeloma
A Phase 2 Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
A Phase 2, Multicohort Open-Label Study of JNJ-68284528 in Subjects with Multiple Myeloma (CARTITUDE-2)
A phase 2, open-label, multicenter study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in adult participants with relapsed or refractory multiple myeloma (QUINTESSENTIAL)
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
A Phase 3 Study Comparing Three Combination Treatments for Newly Diagnosed Multiple Myeloma
A phase 3, two-stage, randomized, multi-center, controlled, open-label study comparing Iberdomide maintenance to Lenalidomide maintenance therapy after ASCT in participants with newly diagnosed multiple myeloma (EXCALIBER-Maintenance)
A Phase 3, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after ASCT in Participants with Newly Diagnosed Multiple Myeloma
A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
A Study of Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for Relapsed Multiple Myeloma
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma When a Stem Cell Transplant is Not a Medically Suitable Treatment
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: The PROTECT Trial
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Testing the Use of Combination Therapy in Adult Patients with Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved